/
HRMY
$35.18-$0.30 (-0.83%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$2.1B
58M shares
52-week range
$25.52 – $40.87
63% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.67%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$6.94
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6.0M | $159.7M | $305.4M | $437.9M | $582.0M | $714.7M | $868.5M |
| Cost of revenue | $184.0K | $1.6M | $27.7M | $55.5M | $83.5M | $121.2M | $156.8M | $198.3M |
| Gross profit | −$184.0K | $4.4M | $132.0M | $249.9M | $354.4M | $460.8M | $557.9M | $670.1M |
| Gross margin | — | 73.7% | 82.6% | 81.8% | 80.9% | 79.2% | 78.1% | 77.2% |
| R&D | $12.4M | $69.6M | $19.4M | $30.4M | $70.9M | $76.1M | $145.8M | $189.6M |
| Operating income | −$41.4M | −$145.9M | $17.0M | $87.5M | $120.2M | $192.0M | $190.8M | $208.5M |
| EBITDA | −$41.3M | −$142.7M | $1.5M | $80.5M | $146.9M | $221.5M | $233.4M | $255.0M |
| Net income | −$39.9M | −$152.0M | −$36.9M | $34.6M | $181.5M | $128.9M | $145.5M | $158.7M |
| Net margin | — | -2535.1% | -23.1% | 11.3% | 41.4% | 22.1% | 20.4% | 18.3% |
| EPS (diluted) | -1.42 | -2.94 | -1.10 | 0.58 | 2.97 | 2.13 | 2.51 | 2.71 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.0B | $3.43 | $2.80–$4.08 | 7 |
| 2027 | $1.1B | $4.13 | $3.41–$5.32 | 6 |
| 2028 | $1.3B | $4.80 | $1.57–$6.18 | 10 |
| 2029 | $1.5B | $6.33 | $5.44–$6.84 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$117.33
Price
$35.17
Implied upside
+234%
Peer comparison
Harmony Biosciences Holdings, Inc. Common Stock
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
www.harmonybiosciences.com- Employees
- 293
- IPO / List date
- Aug 19, 2020
- HQ
- PLYMOUTH MEETING, PA
Held by traders on TradeandTell
No one on the platform currently holds HRMY.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,077,371 | $30.2M |
| Bridgewater Associatesas of 2026-03-31 | 251,506 | $7.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded HRMY yet.
